llness and influenza-like illness to a quadrivalent inactivate
nfluenza vaccine (QIV; Fluarix Quadrivalent, GlaxoSmithKline
iven at 15Âµg dose/strain in adults aged 18 to 64 years37
owever,inconsistencyintheexpressionlevelsoftargetproteins
ue to nonspecific integration of transgene(s) into the hos
enome,hasbeenamajorchallengewithplant-basedexpressio
ystems34.Theunpredictable yieldcould adversely impacttimel
accineproduction,whichtypicallyinvolvesupdatingatleaston
A component of the vaccine to reflect antigenic change i
he circulating influenza viruses each season. A unique positiv
ttribute of plant-derived rHA is that it can stimulate innat
mmunity that predominantly facilitates Type 1 pro-inflammator
ellular immune responses, potentially as a direct effect of th
lant-origin lipids/glycolipids in the vaccine formulation38. Thes
timulatory components in a plant-derived vaccine may need t
econtrolledandkeptataconstantlevel,forcommercialisation
o avoid potential severe adverse events caused by enhance
mmuneresponses invaccinees.